GEORGE OLSEN

General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Rebates for Medicare Part D. Importation. 340B Program. IPI drug pricing proposal, Medicare Rebate Rule. Drug pricing legislation including H.R. 3, Medicare rebate reform, "buy America" proposals, and proposals to impose "most favored nation" pricing on Medicare Part B and D. Policies impacting U.S. address to the Covid-19 pandemic, including American Rescue Plan Act of 2021, P.L. 117-2, H.R. 1319. H.R. 5376. H.R. 3. H.R. 19.

General education about policies impacting pharmaceutical development, approval and reimbursement. H.R. 3, Lower Drug Costs Now Act; Policies impacting pharmaceutical research, development, and approval. Policies impacting public health preparedness and prevention and U.S. address to the Covid-19 pandemic, including the American Rescue Plan Act of 2021, P.L. 117-2, H.R. 1319. 340B Program. H.R. 5376. H.R. 3. H.R. 19. Accelerated Approval pathway; Alzheimers diagnostics policies.

Policies impacting Medicare Part D and Part B reimbursement policies. H.R. 3, Lower Drug Costs Now Act; Policies impacting pharmaceutical research, development, and approval. Policies impacting public health preparedness and prevention and U.S. address to the Covid-19 pandemic, including the American Rescue Plan Act of 2021, P.L. 117-2, H.R. 1319. H.R. 3. H.R. 19.

Legislative and regulatory issues regarding Medicaid managed care; Medicare Advantage issues. Implementation of COVID legislation. Policies impacting U.S. address to the Covid-19 pandemic, including the American Rescue Plan Act of 2021, P.L. 117-2, H.R. 1319. H.R. 5376. Telehealth policies.

Legislative issues related to insurance markets; ACA implementation issues; PBM legislation. Policies impacting U.S. address to the Covid-19 pandemic, including the American Rescue Plan Act of 2021, P.L. 117-2, H.R. 1319. H.R. 5376. Telehealth policies.

President Bidens FY 2022 Budget Proposal, The American Jobs Plan, and The American Families Plan. H.R. 6119, Further Extending Government Funding Act.

Federal funding for alcohol research at NIH; Medical research provisions in COVID-19 relief legislation; Legislation concerning alcohol, alcohol-related diseases, and substance abuse; Security of medical research. Policies impacting the U.S. response to the COVID-19 pandemic in the area of alcohol and substance abuse. Inclusion of alcohol in policy changes related to mental health and substance use disorders. H.R. 6119, Further Extending Government Funding Act.

Tax legislation affecting the Orphan Drug Tax Credit and the Research and Development Tax Credit.

President Bidens FY 2022 Budget Proposal, The American Jobs Plan, and The American Families Plan.

Matters affecting access to and payment for pharmaceuticals under Medicare and Medicare coverage and payment for home infusion of drugs during the COVID-19 pandemic public health emergency. Matters concerning Medicare prescription drug rebate reform, the 340B drug discount program, Buy America requirements, drug importation, and imposition of most favored nation pricing on drugs under Medicare Parts B and D; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and subsequent proposals; H.R. 19, Lower Costs, More Cures Act of 2021; and H.R. 5376, the Build Back Better Act.

Budget reconciliation and President Bidens FY 2022 Budget Proposal, The American Jobs Plan, and The American Families Plan.

Medicare coverage and reimbursement for therapy services and rehabilitation telehealth services; Medicare payment reform for post-acute care services; Matters affecting bundled payments and value-based reimbursement; Proposals to extend coverage and payment for telehealth services after the pandemic public health emergency ends; Extension of moratorium on 2 percent Medicare sequestration and possible Medicare sequestration under PAYGO rules; H.R. 5376, Build Back Better Act; H.R. 5536, Stabilizing Medicare Access to Rehabilitation and Therapy Act.

Matters affecting access to and payment for pharmaceuticals under Medicare; Medicare coverage and payment for home infusion of drugs during the COVID-19 pandemic public health emergency. Legislation concerning Medicare prescription drug rebate reform, the 340B drug discount program, Buy America requirements, drug importation, and imposition of most favored nation pricing on drugs under Medicare Parts B and D; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and subsequent proposals; H.R. 19, Lower Costs, More Cures Act of 2021; and H.R. 5376, the Build Back Better Act.

Matters affecting access to and pricing of pharmaceuticals; matters affecting the Orphan Drug Act and therapies for rare diseases; legislation and regulatory activity relating to importation of prescription drugs; the 340B drug discount program, Buy America requirements; and imposition of most favored nation pricing on drugs. Legislation to improve access to treatments for ALS. President Bidens FY 2022 Budget Proposal, The American Jobs Plan, and The American Families Plan; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and subsequent proposals; H.R. 19, Lower Costs, More Cures Act of 2021; and H.R. 5376, the Build Back Better Act.

Tax issues affecting the pharmaceutical industry including international tax. H.R 3927. S. 2082.

Medicare payment issues including the Independent Payment Advisory Board (IPAB) and Medicaid issues. Medicare Part D. Drug pricing proposals including H.R. 3. Protecting Seniors Through Immunization Act. COVID-19 relief proposals. American Rescue Plan Act of 2021, P.L. 117-2, H.R. 1319. H.R. 3. H.R. 19.

General education about policies impacting pharmaceutical development, approval and reimbursement; Drug safety and drug counterfeiting; Medicare Part D; Federal preemption for prescription drugs; drug importation; and drug shortages. Drug pricing proposals including H.R. 3. Medicare rebate reform, the 340B program, and proposals to impose "most favored nation" pricing on Medicare Part B and D. COVID-19 relief proposals. American Rescue Plan Act of 2021, P.L. 117-2, H.R. 1319. H.R. 5376. H.R. 3. H.R. 19. HR 3927. S. 2082.

General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Rebates for Medicare Part D. Importation. 340B Program. IPI drug pricing proposal, Medicare Rebate Rule. Drug pricing legislation including H.R. 3, Medicare rebate reform, "buy America" proposals, and proposals to impose "most favored nation" pricing on Medicare Part B and D. Policies impacting U.S. address to the Covid-19 pandemic, including American Rescue Plan Act of 2021, P.L. 117-2, H.R. 1319. H.R. 5376. H.R. 3. H.R. 19.

General education about policies impacting pharmaceutical development, approval and reimbursement. H.R. 3, Lower Drug Costs Now Act; Policies impacting pharmaceutical research, development, and approval. Policies impacting public health preparedness and prevention and U.S. address to the Covid-19 pandemic, including the American Rescue Plan Act of 2021, P.L. 117-2, H.R. 1319. 340B Program. H.R. 5376. H.R. 3. H.R. 19.

Policies impacting Medicare Part D and Part B reimbursement policies. H.R. 3, Lower Drug Costs Now Act; Policies impacting pharmaceutical research, development, and approval. Policies impacting public health preparedness and prevention and U.S. address to the Covid-19 pandemic, including the American Rescue Plan Act of 2021, P.L. 117-2, H.R. 1319. H.R. 3. H.R. 19.

Legislative issues related to insurance markets; ACA implementation issues; PBM legislation. Policies impacting U.S. address to the Covid-19 pandemic, including the American Rescue Plan Act of 2021, P.L. 117-2, H.R. 1319. H.R. 5376.

Legislative and regulatory issues regarding Medicaid managed care; Medicare Advantage issues. Implementation of COVID legislation. Policies impacting U.S. address to the Covid-19 pandemic, including the American Rescue Plan Act of 2021, P.L. 117-2, H.R. 1319. H.R. 5376.

General education about educational accreditation, quality standards, and fair and effective processes.

Federal funding for alcohol research at NIH; Medical research provisions in COVID-19 relief legislation; Legislation concerning alcohol, alcohol-related diseases, and substance abuse; Security of medical research. Policies impacting the U.S. response to the COVID-19 pandemic in the area of alcohol and substance abuse. H.R. 6119, Further Extending Government Funding Act.

President Bidens FY 2022 Budget Proposal, The American Jobs Plan, and The American Families Plan. H.R. 6119, Further Extending Government Funding Act.

Tax legislation affecting the Orphan Drug Tax Credit and the Research and Development Tax Credit.

Matters affecting access to and payment for pharmaceuticals under Medicare and Medicare coverage and payment for home infusion of drugs during the COVID-19 pandemic public health emergency. Matters concerning Medicare prescription drug rebate reform, the 340B drug discount program, Buy America requirements, drug importation, and imposition of most favored nation pricing on drugs under Medicare Parts B and D; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and subsequent proposals; H.R. 19, Lower Costs, More Cures Act of 2021; and H.R. 5376, the Build Back Better Act.

Budget reconciliation and President Bidens FY 2022 Budget Proposal, The American Jobs Plan, and The American Families Plan.

Legislation affecting health care providers in response to the COVID-19 pandemic. President Bidens FY 2022 Budget Proposal, The American Jobs Plan, and The American Families Plan. H.R. 5376, Build Back Better Act.

Medicare coverage and reimbursement for therapy services and rehabilitation telehealth services; Medicare payment reform for post-acute care services; Matters affecting bundled payments and value-based reimbursement; and legislation to waive or modify the budget neutrality requirement for E/M codes under the CY 2021 physician fee schedule; Proposals to extend coverage and payment for telehealth services after the pandemic public health emergency ends; Extension of moratorium on 2 percent Medicare sequestration (H.R. 1868) and possible Medicare sequestration under PAYGO rules. H.R. 5376, Build Back Better Act; S. 610, Protecting Medicare and American Farmers from Sequester Cuts Act.

Matters affecting access to and payment for pharmaceuticals under Medicare; Medicare coverage and payment for home infusion of drugs during the COVID-19 pandemic public health emergency. Legislation concerning Medicare prescription drug rebate reform, the 340B drug discount program, Buy America requirements, drug importation, and imposition of most favored nation pricing on drugs under Medicare Parts B and D; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and subsequent proposals; H.R. 19, Lower Costs, More Cures Act of 2021; and H.R. 5376, the Build Back Better Act.

Budget reconciliation and President Bidens FY 2022 Budget Proposal, The American Jobs Plan, and The American Families Plan.

General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Rebates for Medicare Part D. Importation. 340B Program. IPI drug pricing proposal, Medicare Rebate Rule. Drug pricing legislation including H.R. 3, Medicare rebate reform, "buy America" proposals, and proposals to impose "most favored nation" pricing on Medicare Part B and D. Policies impacting U.S. address to the Covid-19 pandemic, including American Rescue Plan Act of 2021, P.L. 117-2, H.R. 1319. H.R. 5376. H.R. 3. H.R. 19.

Tax issues affecting the pharmaceutical industry including international tax.

Medicare payment issues including the Independent Payment Advisory Board (IPAB) and Medicaid issues. Medicare Part D. Drug pricing proposals including H.R. 3. Protecting Seniors Through Immunization Act. COVID-19 relief proposals. American Rescue Plan Act of 2021, P.L. 117-2, H.R. 1319. H.R. 3. H.R. 19.

General education about policies impacting pharmaceutical development, approval and reimbursement; Drug safety and drug counterfeiting; Medicare Part D; Federal preemption for prescription drugs; drug importation; and drug shortages. Drug pricing proposals including H.R. 3. Medicare rebate reform, the 340B program, and proposals to impose "most favored nation" pricing on Medicare Part B and D. COVID-19 relief proposals. American Rescue Plan Act of 2021, P.L. 117-2, H.R. 1319. H.R. 5376. H.R. 3. H.R. 19.

Policies impacting Medicare Part D and Part B reimbursement policies. H.R. 3, Lower Drug Costs Now Act; Policies impacting pharmaceutical research, development, and approval. Policies impacting public health preparedness and prevention and U.S. address to the Covid-19 pandemic, including the American Rescue Plan Act of 2021, P.L. 117-2, H.R. 1319. H.R. 3. H.R. 19.

General education about policies impacting pharmaceutical development, approval and reimbursement. H.R. 3, Lower Drug Costs Now Act; Policies impacting pharmaceutical research, development, and approval. Policies impacting public health preparedness and prevention and U.S. address to the Covid-19 pandemic, including the American Rescue Plan Act of 2021, P.L. 117-2, H.R. 1319. 340B Program. H.R. 5376. H.R. 3. H.R. 19.

Legislative and regulatory issues regarding Medicaid managed care; Medicare Advantage issues. Implementation of COVID legislation. Policies impacting U.S. address to the Covid-19 pandemic, including the American Rescue Plan Act of 2021, P.L. 117-2, H.R. 1319.

Legislative issues related to insurance markets; ACA implementation issues; PBM legislation. Policies impacting U.S. address to the Covid-19 pandemic, including the American Rescue Plan Act of 2021, P.L. 117-2, H.R. 1319.

General education about educational accreditation, quality standards, and fair and effective processes.

Federal funding for alcohol research at NIH; Medical research provisions in COVID-19 relief legislation; Legislation concerning alcohol, alcohol-related diseases, and substance abuse; Security of medical research. Policies impacting the U.S. response to the COVID-19 pandemic in the area of alcohol and substance abuse.

President Bidens FY 2022 Budget Proposal, The American Jobs Plan, and The American Families Plan.

Policies to ensure an adequate supply of blood plasma; Drug safety and drug counterfeiting; Policies affecting pre-existing condition protections; Drug importation; Policies impacting the U.S. response to the COVID-19 pandemic; Legislation impacting drug pricing including Medicare rebate reform, the 340B drug discount program, Buy America requirements, and imposition of most favored nation pricing on drugs under Medicare and the commercial market. Legislation to increase awareness of need for plasma donations. Budget reconciliation and President Bidens FY 2022 Budget Proposal, The American Jobs Plan, and The American Families Plan; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and subsequent proposals; H.R. 19, Lower Costs, More Cures Act of 2021; and H.R. 5376, the Build Back Better Act; Matters affecting plasma donation and potential plasma shortages.

Matters affecting access to and payment for pharmaceuticals under Medicare and Medicare coverage and payment for home infusion of drugs during the COVID-19 pandemic public health emergency. Matters concerning Medicare prescription drug rebate reform, the 340B drug discount program, Buy America requirements, drug importation, and imposition of most favored nation pricing on drugs under Medicare Parts B and D; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and subsequent proposals; H.R. 19, Lower Costs, More Cures Act of 2021; and H.R. 5376, the Build Back Better Act.

Medicare coverage and reimbursement for therapy services and rehabilitation telehealth services; Medicare payment reform for post-acute care services; Matters affecting bundled payments and value-based reimbursement; and legislation to waive or modify the budget neutrality requirement for E/M codes under the CY 2021 physician fee schedule; Proposals to extend coverage and payment for telehealth services after the pandemic public health emergency ends; Extension of moratorium on 2 percent Medicare sequestration (H.R. 1868) and possible Medicare sequestration under PAYGO rules.

Budget reconciliation and President Bidens FY 2022 Budget Proposal, The American Jobs Plan, and The American Families Plan.

Budget reconciliation and President Bidens FY 2022 Budget Proposal, The American Jobs Plan, and The American Families Plan.

Matters affecting access to and payment for pharmaceuticals under Medicare; Medicare coverage and payment for home infusion of drugs during the COVID-19 pandemic public health emergency. Legislation concerning Medicare prescription drug rebate reform, the 340B drug discount program, Buy America requirements, drug importation, and imposition of most favored nation pricing on drugs under Medicare Parts B and D; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and subsequent proposals; H.R. 19, Lower Costs, More Cures Act of 2021; and H.R. 5376, the Build Back Better Act.

Medicare payment issues including the Independent Payment Advisory Board (IPAB) and Medicaid issues. Medicare Part D. Drug pricing proposals including H.R. 3. Protecting Seniors Through Immunization Act. COVID-19 relief proposals. American Rescue Plan Act of 2021, P.L. 117-2, H.R. 1319.

General education about policies impacting pharmaceutical development, approval and reimbursement; Drug safety and drug counterfeiting; Medicare Part D; Federal preemption for prescription drugs; drug importation; and drug shortages. Drug pricing proposals including H.R. 3. Medicare rebate reform, the 340B program, and proposals to impose "most favored nation" pricing on Medicare Part B and D. COVID-19 relief proposals. American Rescue Plan Act of 2021, P.L. 117-2, H.R. 1319.

General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Rebates for Medicare Part D. Importation. 340B Program. IPI drug pricing proposal, Medicare Rebate Rule. Drug pricing legislation including H.R. 3, Medicare rebate reform, "buy America" proposals, and proposals to impose "most favored nation" pricing on Medicare Part B and D. Policies impacting U.S. address to the Covid-19 pandemic, including American Rescue Plan Act of 2021, P.L. 117-2, H.R. 1319.

General education about policies impacting pharmaceutical development, approval and reimbursement. H.R. 3, Lower Drug Costs Now Act; Policies impacting pharmaceutical research, development, and approval. Policies impacting public health preparedness and prevention and U.S. address to the Covid-19 pandemic, including the American Rescue Plan Act of 2021, P.L. 117-2, H.R. 1319. 340B Program.

Policies impacting Medicare Part D and Part B reimbursement policies. H.R. 3, Lower Drug Costs Now Act; Policies impacting pharmaceutical research, development, and approval. Policies impacting public health preparedness and prevention and U.S. address to the Covid-19 pandemic, including the American Rescue Plan Act of 2021, P.L. 117-2, H.R. 1319.

Legislative and regulatory issues regarding Medicaid managed care; Medicare Advantage issues. Implementation of COVID legislation. Policies impacting U.S. address to the Covid-19 pandemic, including the American Rescue Plan Act of 2021, P.L. 117-2, H.R. 1319.

Legislative issues related to insurance markets; ACA implementation issues; PBM legislation. Policies impacting U.S. address to the Covid-19 pandemic, including the American Rescue Plan Act of 2021, P.L. 117-2, H.R. 1319.

General education about educational accreditation, quality standards, and fair and effective processes.

Federal funding for alcohol research at NIH; Medical research provisions in COVID-19 relief legislation; Legislation concerning alcohol, alcohol-related diseases, and substance abuse; Security of medical research. Policies impacting the U.S. response to the COVID-19 pandemic in the area of alcohol and substance abuse.

President Bidens FY 2022 Budget Proposal, The American Jobs Plan, and The American Families Plan.

President Bidens FY 2022 Budget Proposal, The American Jobs Plan, and The American Families Plan.

Tax legislation affecting the Orphan Drug Tax Credit and the Research and Development Tax Credit.

Matters affecting access to and payment for pharmaceuticals under Medicare and Medicare coverage and payment for home infusion of drugs during the COVID-19 pandemic public health emergency. Matters concerning Medicare prescription drug rebate reform, the 340B drug discount program, Buy America requirements, drug importation, and imposition of most favored nation pricing on drugs under Medicare Parts B and D.

Legislation affecting health care providers in response to the COVID-19 pandemic. President Bidens FY 2022 Budget Proposal, The American Jobs Plan, and The American Families Plan.

Budget reconciliation and President Bidens FY 2022 Budget Proposal, The American Jobs Plan, and The American Families Plan.

Medicare coverage and reimbursement for therapy services and rehabilitation telehealth services; Medicare payment reform for post-acute care services; Matters affecting bundled payments and value-based reimbursement; Implementation of physician fee schedule for CY 2020; and legislation to waive or modify the budget neutrality requirement for E/M codes under the CY 2021 physician fee schedule; Proposals to extend coverage and payment for telehealth services after the pandemic public health emergency ends; Extension of moratorium on 2 percent Medicare sequestration (H.R. 1868) and possible Medicare sequestration under PAYGO rules.

Matters affecting access to and pricing of pharmaceuticals; matters affecting the Orphan Drug Act and therapies for rare diseases; legislation and regulatory activity relating to importation of prescription drugs; the 340B drug discount program, Buy America requirements; and imposition of most favored nation pricing on drugs. Legislation to improve access to treatments for ALS. President Bidens FY 2022 Budget Proposal, The American Jobs Plan, and The American Families Plan.

Matters affecting access to and payment for pharmaceuticals under Medicare; Medicare coverage and payment for home infusion of drugs during the COVID-19 pandemic public health emergency. Legislation concerning Medicare prescription drug rebate reform, the 340B drug discount program, Buy America requirements, drug importation, and imposition of most favored nation pricing on drugs under Medicare Parts B and D.

General education on Issues related to the Drug Enforcement Agency (DEA); issues related to opioid addiction and treatment, including NIH/HHS funding levels; Policies impacting the US efforts to address the Covid 19 pandemic, including the American Rescue Plan Act of 2021.

General education about educational accreditation, quality standards, and fair and effective processes.

Medicare payment issues including the Independent Payment Advisory Board (IPAB) and Medicaid issues. Medicare Part D. Drug pricing proposals including H.R. 3. Protecting Seniors Through Immunization Act. COVID-19 relief proposals. American Rescue Plan Act of 2021, P.L. 117-2, H.R. 1319.

General education about policies impacting pharmaceutical development, approval and reimbursement; Drug safety and drug counterfeiting; Medicare Part D; Federal preemption for prescription drugs; drug importation; and drug shortages. Drug pricing proposals including H.R. 3. Medicare rebate reform, the 340B program, and proposals to impose "most favored nation" pricing on Medicare Part B and D. COVID-19 relief proposals. American Rescue Plan Act of 2021, P.L. 117-2, H.R. 1319.

General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Rebates for Medicare Part D. Importation. 340B Program. IPI drug pricing proposal, Medicare Rebate Rule. Drug pricing legislation including H.R. 3, Medicare rebate reform, "buy America" proposals, and proposals to impose "most favored nation" pricing on Medicare Part B and D. Policies impacting U.S. address to the Covid-19 pandemic, including American Rescue Plan Act of 2021, P.L. 117-2, H.R. 1319.

Policies impacting Medicare Part D and Part B reimbursement policies. H.R. 3, Lower Drug Costs Now Act; Policies impacting pharmaceutical research, development, and approval. Policies impacting public health preparedness and prevention and U.S. address to the Covid-19 pandemic, including the American Rescue Plan Act of 2021, P.L. 117-2, H.R. 1319.

General education about policies impacting pharmaceutical development, approval and reimbursement. H.R. 3, Lower Drug Costs Now Act; Policies impacting pharmaceutical research, development, and approval. Policies impacting public health preparedness and prevention and U.S. address to the Covid-19 pandemic, including the American Rescue Plan Act of 2021, P.L. 117-2, H.R. 1319. 340B Program.

Legislative and regulatory issues regarding Medicaid managed care; Medicare Advantage issues. Implementation of COVID legislation. Policies impacting U.S. address to the Covid-19 pandemic, including the American Rescue Plan Act of 2021, P.L. 117-2, H.R. 1319.

Legislative issues related to insurance markets; ACA implementation issues; PBM legislation. Policies impacting U.S. address to the Covid-19 pandemic, including the American Rescue Plan Act of 2021, P.L. 117-2, H.R. 1319.

Federal funding for alcohol research at NIH; Medical research provisions in COVID-19 relief legislation; Legislation concerning alcohol, alcohol-related diseases, and substance abuse; Security of medical research. Policies impacting the U.S. response to the COVID-19 pandemic including the American Rescue Plan Act of 2021 (H.R. 1319, now Public Law No. 117-2).

Budget reconciliation and the American Rescue Plan Act of 2021 (H.R. 1319, now Public Law No. 117-2).

Policies to ensure an adequate supply of blood plasma; Drug safety and drug counterfeiting; Policies affecting pre-existing condition protections; Drug importation; Policies impacting the U.S. response to the COVID-19 pandemic; Legislation impacting drug pricing including Medicare rebate reform, the 340B drug discount program, Buy America requirements, and imposition of most favored nation pricing on drugs under Medicare Parts B and D. Legislation to increase awareness of need for plasma donations. Budget reconciliation and the American Rescue Plan Act of 2021 (H.R. 1319, now Public Law No. 117-2).

Matters affecting access to and payment for pharmaceuticals under Medicare; Medicare coverage and payment for home infusion of drugs during the COVID-19 pandemic public health emergency. Matters concerning Medicare prescription drug rebate reform, the 340B drug discount program, Buy America requirements, drug importation, and imposition of most favored nation pricing on drugs under Medicare Parts B and D. The American Rescue Plan Act of 2021 (H.R. 1319, now Public Law No. 117-2).

Tax legislation affecting the Orphan Drug Tax Credit and the Research and Development Tax Credit.

Budget reconciliation and the American Rescue Plan Act of 2021 (H.R. 1319, now Public Law No. 117-2).

Matters affecting access to and payment for pharmaceuticals under Medicare; Medicare coverage and payment for home infusion of drugs during the COVID-19 pandemic public health emergency. Matters concerning Medicare prescription drug rebate reform, the 340B drug discount program, Buy America requirements, drug importation, and imposition of most favored nation pricing on drugs under Medicare Parts B and D. The American Rescue Plan Act of 2021 (H.R. 1319, now Public Law No. 117-2).

Legislation affecting health care providers in response to the COVID-19 pandemic including the American Rescue Plan Act of 2021 (H.R. 1319, now Public Law No. 117-2).

Budget reconciliation and the American Rescue Plan Act of 2021 (H.R. 1319, now Public Law No. 117-2).

Medicare coverage and reimbursement for therapy services and rehabilitation telehealth services; Medicare payment reform for post-acute care services; Matters affecting bundled payments and value-based reimbursement; Implementation of physician fee schedule for CY 2020; Legislation to waive or modify the budget neutrality requirement for E/M codes under the CY 2021 physician fee schedule; The American Rescue Plan Act of 2021 (H.R. 1319, now Public Law No. 117-2). Extension of moratorium on 2 percent Medicare sequestration (H.R. 1868).

Matters affecting access to and payment for pharmaceuticals under Medicare; Medicare coverage and payment for home infusion of drugs during the COVID-19 pandemic public health emergency. Matters concerning Medicare prescription drug rebate reform, the 340B drug discount program, Buy America requirements, drug importation, and imposition of most favored nation pricing on drugs under Medicare Parts B and D. The American Rescue Plan Act of 2021 (H.R. 1319, now Public Law No. 117-2).

Matters affecting access to and pricing of pharmaceuticals; matters affecting the Orphan Drug Act and therapies for rare diseases; legislation and regulatory activity relating to importation of prescription drugs; drug pricing including Medicare rebate reform, the 340B drug discount program, Buy America requirements, and imposition of most favored nation pricing on drugs under Medicare Parts B and D. Legislation to improve access to treatments for ALS. The American Rescue Plan Act of 2021 (H.R. 1319, now Public Law No. 117-2).

General education on Issues related to the Drug Enforcement Agency (DEA); issues related to opioid addiction and treatment, including NIH/HHS funding levels; Policies impacting the US efforts to address the Covid 19 pandemic, including the American Rescue Plan Act of 2021.

Medicare payment issues including the Independent Payment Advisory Board (IPAB) and Medicaid issues. Medicare Part D. 101 drug pricing. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019. Vaccine legislation; H.R. 5076, S. 1872. Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136. Education regarding Executive Orders impacting drug pricing including Medicare rebate reform, the 340 B program, "buy America" proposals, and proposals to impose "most favored nation" pricing on Medicare Part B and D. H.R. 133, Consolidated Appropriations Act, 2021, Public Law No: 116-260.

General education about policies impacting pharmaceutical development, approval and reimbursement; Drug safety and drug counterfeiting; Medicare Part D; Federal preemption for prescription drugs; drug importation; and drug shortages. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019. Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136. Education regarding Executive Orders impacting drug pricing including Medicare rebate reform, the 340 B program, "buy America" proposals, and proposals to impose "most favored nation" pricing on Medicare Part B and D. H.R. 133, Consolidated Appropriations Act, 2021, Public Law No: 116-260.

General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Rebates for Medicare Part D. Importation. 340B Drug Pricing Program. IPI drug pricing proposal, Medicare Rebate Rule. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019. Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136. H.R. 1425, Patient Protection and Affordable Care Enhancement Act. Education regarding Executive Orders impacting drug pricing including Medicare rebate reform, the 340 B program, "buy America" proposals, and proposals to impose "most favored nation" pricing on Medicare Part B and D. H.R. 133, Consolidated Appropriations Act, 2021, Public Law No: 116-260.

General education about policies impacting pharmaceutical development, approval and reimbursement. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019. FY 2021 Appropriations. Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136. Education regarding Executive Orders impacting drug pricing including Medicare rebate reform, the 340 B program, "buy America" proposals, and proposals to impose "most favored nation" pricing on Medicare Part B and D. H.R. 133, Consolidated Appropriations Act, 2021, Public Law No: 116-260.

Policies impacting Medicare Part D and Part B reimbursement policies. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019. Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136. Education regarding Executive Orders impacting drug pricing including Medicare rebate reform, the 340 B program, "buy America" proposals, and proposals to impose "most favored nation" pricing on Medicare Part B and D. H.R. 133, Consolidated Appropriations Act, 2021, Public Law No: 116-260.

Legislative issues related to insurance markets; ACA implementation issues; PBM legislation. Policies impacting U.S. address to the COVID-19 pandemic, including H.R. 6201, Families First Coronavirus Response Act and H.R. 748. H.R. 133, Consolidated Appropriations Act, 2021, Public Law No: 116-260

Legislative and regulatory issues regarding Medicaid managed care; Medicare Advantage issues. S. 1895. Policies impacting U.S. address to the COVID-19 pandemic, including H.R. 6201, Families First Coronavirus Response Act and H.R. 748. Medicare Advantage Star Rating Policy; H.R. 6926, MIND ACT. H.R. 133, Consolidated Appropriations Act, 2021, Public Law No: 116-260

Issues related to Drug Enforcement Agency (DEC) implementation of S. 916; Reimbursement issues; issues related to opioid addiction; issues related to NIH/HHS funding levels; issues related to funding for CARA, medication assisted treatment and 21st Century Cures Act; Implementation of CARA Act. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 4712 Fairness in Orphan Drug Exclusivity Act. Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136. Policies impacting orphan drug approval and reimbursement, including H.R. 4712/S. 3272, Fairness in Orphan Drug Exclusivity Act; and H.R. 133, Consolidated Appropriations Act, 2021, Public Law No: 116-260.

General education about policies impact pharmaceutical development, approval, and reimbursement including Medicare payment policies. Medicare Part D. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019. Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136. Education regarding Executive Orders impacting drug pricing including Medicare rebate reform, the 340 B program, "buy America" proposals, and proposals to impose "most favored nation" pricing on Medicare Part B and D; and H.R. 133, Consolidated Appropriations Act, 2021, Public Law No: 116-260.

General education about federal policies impact pharmaceutical development, approval, and reimbursement (including Medicare, Medicaid, ACA issues). General education about FDA approval policies; Drug pricing under 340B Program; IPI drug pricing proposal. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019. Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136. Education regarding Executive Orders impacting drug pricing including Medicare rebate reform, the 340 B program, "buy America" proposals, and proposals to impose "most favored nation" pricing on Medicare Part B and D; and H.R. 133, Consolidated Appropriations Act, 2021, Public Law No: 116-260.

Tax issues affecting the pharmaceutical industry and the Orphan Drug tax Credit.

H.R. 8337, Continuing Appropriations Act, 2021 and Other Extensions Act. H.R. 133, Consolidated Appropriations Act, 2021, Pub. L. No. 116-260.

S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019; Issues concerning BARDA funding; S. 551, Recovering Excessive Funds for Unused and Needless Drugs Act 2019; Drug importation including S. 61 and H.R. 478, Safe and Affordable Drugs from Canada Act of 2019; S. 97 and H.R. 447, Affordable and Safe Prescription Drug Importation Act; Legislation affecting pharmaceutical pricing including the Lower Heath Care Costs Act of 2019 (S.1895), Affordable Prescriptions for Patients Act of 2019 (S. 1416), Fair Accountability and Innovative Research Drug Pricing Act of 2019 (S. 1391, Transparent Drug Pricing Act of 2019 (S. 977), CREATES Act of 2019 (H.R. 965, S. 340), Medicare Negotiation and Competitive Licensing Act of 2019 (H.R. 1046), Strengthening Health Care and Lowering Prescription Drug Costs Act (H.R. 987). Policies impacting the U.S. response to the COVID-19 pandemic including H.R. 604, the Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No. 116-123; H.R. 6201, Families First Coronavirus Response Act, Public Law No. 116-127; H.R. 748, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act"), Public Law No. 116-136; and H.R. 6800, the Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES Act"). H.R. 2279/S.2546, the Safe Step Act. Policies to ensure an adequate supply of plasma generally and for the development of therapies for COVID-19. Education regarding Executive Orders impacting drug pricing including Medicare rebate reform, the 340B drug discount program, Buy America requirements, drug importation, and imposition of most favored nation pricing on drugs under Medicare Parts B and D. Legislation to increase awareness of need for plasma donations including H.R. 7783/S. 4179, the Plasma Donation Awareness Act of 2020. H.R. 133, Consolidated Appropriations Act, 2021, Pub. L. No. 116-260.

Federal funding for alcohol research at NIH; Medical research provisions in Labor, Health and Human Services, and Education Appropriations bill; Legislation concerning alcohol, alcohol-related diseases, and substance abuse; Security of medical research. Policies impacting the U.S. response to the COVID-19 pandemic including H.R. 604, the Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No. 116-123; H.R. 6201, Families First Coronavirus Response Act, Public Law No. 116-127; H.R. 748, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), Public Law No. 116-136; and H.R. 6800, the Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES Act"). H.R. 133, Consolidated Appropriations Act, 2021, Pub. L. No. 116-260.

H.R. 8337, Continuing Appropriations Act, 2021 and Other Extensions Act. H.R. 133, Consolidated Appropriations Act, 2021, Pub. L. No. 116-260.

H.R. 8337, Continuing Appropriations Act, 2021 and Other Extensions Act. H.R. 133, Consolidated Appropriations Act, 2021, Pub. L. No. 116-260.

Tax legislation affecting the Orphan Drug Tax Credit and the Research and Development Tax Credit.

Drug safety and drug counterfeiting; H.R. 2905, Medicare IVIG Access Enhancement Act; Policies affecting pre-existing condition protections; Drug importation including S. 61 and H.R. 478, Safe and Affordable Drugs from Canada Act of 2019; S. 97 and H.R. 447, Affordable and Safe Prescription Drug Importation Act; S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3; Lower Drug Costs Now Act of 2019; Policies impacting the U.S. response to the COVID-19 pandemic including H.R. 604, the Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No. 116-123; H.R. 6201, Families First Coronavirus Response Act, Public Law No. 116-127; H.R. 748, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act"), Public Law No. 116-136; and H.R. 6800, the Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES Act"). Education regarding Executive Orders impacting drug pricing including Medicare rebate reform, the 340B drug discount program, Buy America requirements, drug importation, and imposition of most favored nation pricing on drugs under Medicare Parts B and D. Legislation to increase awareness of need for plasma donations including H.R. 7783/S. 4179, the Plasma Donation Awareness Act of 2020. H.R. 133, Consolidated Appropriations Act, 2021, Pub. L. No. 116-260.

Physical Therapist Workforce and Patient Access Act (S. 970); Policies impacting the U.S. response to the COVID-19 pandemic including H.R. 604, the Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No. 116-123; H.R. 6201, Families First Coronavirus Response Act, Public Law No. 116-127; H.R. 748, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), Public Law No. 116-136; and H.R. 6800, the Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES Act"). H.R. 133, Consolidated Appropriations Act, 2021, Pub. L. No. 116-260.

Medicare coverage and reimbursement for therapy services and rehabilitation telehealth services including H.R. 7154, the Outpatient Therapy Modernization and Stabilization Act; Policies impacting the U.S. response to the COVID-19 pandemic including H.R. 604, the Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No. 116-123; H.R. 6201, Families First Coronavirus Response Act, Public Law No. 116-127; H.R. 748, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), Public Law No. 116-136; and H.R. 6800, the Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES Act). Medicare payment reform for post acute care services. Matters affecting bundled payments and value-based reimbursement; Implementation of physician fee schedule for CY 2020. Legislation to waive the budget neutrality requirement for E/M codes under the CY 2021 physician fee schedule including H.R. 8505. S. 5007, Holding Providers Harmless from Medicare Cuts During COVID-19 Act of 2020; H.R. 8702, Holding Providers Harmless from Medicare Cuts During COVID-19 Act of 2020. H.R. 133, Consolidated Appropriations Act, 2021, Pub. L. No. 116-260.

Matters affecting access to and pricing of pharmaceuticals. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and HR 3, Lower Drug Costs Now Act of 2019. Policies impacting the U.S. response to the COVID-19 pandemic including H.R. 604, the Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No. 116-123; H.R. 6201, Families First Coronavirus Response Act, Public Law No. 116-127; H.R. 748, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), Public Law No. 116-136; and H.R. 6800, the Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES Act). Medicare coverage and payment for home infusion of drugs during the COVID-19 pandemic public health emergency. Education regarding Executive Orders impacting drug pricing including Medicare rebate reform, the 340B drug discount program, Buy America requirements, drug importation, and imposition of most favored nation pricing on drugs under Medicare Parts B and D. H.R. 133, Consolidated Appropriations Act, 2021, Pub. L. No. 116-260.

Medicare payment issues including the Independent Payment Advisory Board (IPAB) and Medicaid issues. Medicare Part D. 101 drug pricing. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019. Vaccine legislation; H.R. 5076, S. 1872. Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136. Education regarding Executive Orders impacting drug pricing including Medicare rebate reform, the 340 B program, "buy America" proposals, and proposals to impose "most favored nation" pricing on Medicare Part B and D.

General education about policies impacting pharmaceutical development, approval and reimbursement; Drug safety and drug counterfeiting; Medicare Part D; Federal preemption for prescription drugs; drug importation; and drug shortages. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019. Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136. Education regarding Executive Orders impacting drug pricing including Medicare rebate reform, the 340 B program, "buy America" proposals, and proposals to impose "most favored nation" pricing on Medicare Part B and D.

General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Rebates for Medicare Part D. Importation. 340B Drug Pricing Program. IPI drug pricing proposal, Medicare Rebate Rule. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019. Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136. H.R. 1425, Patient Protection and Affordable Care Enhancement Act. Education regarding Executive Orders impacting drug pricing including Medicare rebate reform, the 340 B program, "buy America" proposals, and proposals to impose "most favored nation" pricing on Medicare Part B and D.

Policies impacting Medicare Part D and Part B reimbursement policies. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019. Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136. Education regarding Executive Orders impacting drug pricing including Medicare rebate reform, the 340 B program, "buy America" proposals, and proposals to impose "most favored nation" pricing on Medicare Part B and D.

General education about policies impacting pharmaceutical development, approval and reimbursement. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019. FY 2021 Appropriations. Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136. Education regarding Executive Orders impacting drug pricing including Medicare rebate reform, the 340 B program, "buy America" proposals, and proposals to impose "most favored nation" pricing on Medicare Part B and D.

Legislative issues related to insurance markets; ACA implementation issues; PBM legislation. Policies impacting U.S. address to the COVID-19 pandemic, including H.R. 6201, Families First Coronavirus Response Act and H.R. 748.

Legislative and regulatory issues regarding Medicaid managed care; Medicare Advantage issues. S. 1895. Policies impacting U.S. address to the COVID-19 pandemic, including H.R. 6201, Families First Coronavirus Response Act and H.R. 748. Medicare Advantage Star Rating Policy; H.R. 6926, MIND ACT

Tax issues affecting the pharmaceutical industry and the Orphan Drug tax Credit.

S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019; Issues concerning BARDA funding; S. 551, Recovering Excessive Funds for Unused and Needless Drugs Act 2019; Drug importation including S. 61 and H.R. 478, Safe and Affordable Drugs from Canada Act of 2019; S. 97 and H.R. 447, Affordable and Safe Prescription Drug Importation Act; Legislation affecting pharmaceutical pricing including the Lower Heath Care Costs Act of 2019 (S.1895), Affordable Prescriptions for Patients Act of 2019 (S. 1416), Fair Accountability and Innovative Research Drug Pricing Act of 2019 (S. 1391, Transparent Drug Pricing Act of 2019 (S. 977), CREATES Act of 2019 (H.R. 965, S. 340), Medicare Negotiation and Competitive Licensing Act of 2019 (H.R. 1046), Strengthening Health Care and Lowering Prescription Drug Costs Act (H.R. 987). Policies impacting the U.S. response to the COVID-19 pandemic including H.R. 604, the Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No. 116-123; H.R. 6201, Families First Coronavirus Response Act, Public Law No. 116-127; H.R. 748, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act"), Public Law No. 116-136; and H.R. 6800, the Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES Act"). H.R. 2279/S.2546, the Safe Step Act. Policies to ensure an adequate supply of plasma generally and for the development of therapies for COVID-19. Education regarding Executive Orders impacting drug pricing including Medicare rebate reform, the 340B drug discount program, Buy America requirements, drug importation, and imposition of most favored nation pricing on drugs under Medicare Parts B and D. Legislation to increase awareness of need for plasma donations including H.R. 7783/S. 4179, the Plasma Donation Awareness Act of 2020.

H.R. 8337, Continuing Appropriations Act, 2021 and Other Extensions Act.

Federal funding for alcohol research at NIH; Medical research provisions in Labor, Health and Human Services, and Education Appropriations bill; Legislation concerning alcohol, alcohol-related diseases, and substance abuse; Security of medical research. Policies impacting the U.S. response to the COVID-19 pandemic including H.R. 604, the Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No. 116-123; H.R. 6201, Families First Coronavirus Response Act, Public Law No. 116-127; H.R. 748, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), Public Law No. 116-136; and H.R. 6800, the Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES Act").

Payment policies for Medicare Part B prescription drugs; Medicare drug coverage and payment policies for plasma protein products. Medicare coverage and payment for home infusion of drugs generally and during the COVID-19 public health emergency. Policies impacting the U.S. response to the COVID-19 pandemic including H.R. 604, the Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No. 116-123; H.R. 6201, Families First Coronavirus Response Act, Public Law No. 116-127; H.R. 748, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), Public Law No. 116-136; and H.R. 6800, the Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES Act). S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019. Education regarding Executive Orders impacting drug pricing including Medicare rebate reform, the 340B drug discount program, Buy America requirements, drug importation, and imposition of most favored nation pricing on drugs under Medicare Parts B and D. H.R. 7839, the Continuing Access to In-Home IVIG Act.

H.R. 8337, Continuing Appropriations Act, 2021 and Other Extensions Act.

Coverage of physical therapy assistants under TRICARE; Implementation of National Defense Authorization Act for FY 2018.

Medicare coverage and reimbursement for therapy services and rehabilitation telehealth services including H.R. 7154, the Outpatient Therapy Modernization and Stabilization Act; Policies impacting the U.S. response to the COVID-19 pandemic including H.R. 604, the Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No. 116-123; H.R. 6201, Families First Coronavirus Response Act, Public Law No. 116-127; H.R. 748, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), Public Law No. 116-136; and H.R. 6800, the Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES Act). Medicare payment reform for post acute care services. Matters affecting bundled payments and value-based reimbursement; Implementation of physician fee schedule for CY 2020. Legislation to waive the budget neutrality requirement for E/M codes under the CY 2021 physician fee schedule including H.R. 8505.

Matters affecting access to and pricing of pharmaceuticals; matters affecting the Orphan Drug Act and therapies for rare diseases; legislation and regulatory activity relating to importation of prescription drugs, including S. 61 and H.R. 478, Safe and Affordable Drugs from Canada Act of 2019; S. 97 and H.R. 447, Affordable and Safe Prescription Drug Importation Act; S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3; Lower Drug Costs Now Act of 2019; Policies impacting the U.S. response to the COVID-19 pandemic including H.R. 604, the Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No. 116-123; H.R. 6201, Families First Coronavirus Response Act, Public Law No. 116-127; H.R. 748, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), Public Law No. 116-136; and H.R. 6800, the Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES Act"). Education regarding Executive Orders impacting drug pricing including Medicare rebate reform, the 340B drug discount program, Buy America requirements, drug importation, and imposition of most favored nation pricing on drugs under Medicare Parts B and D. H.R. 1407/S.578, ALS Disability Insurance Access Act; and H.R. 7071, Accelerate Access to Critical Therapies for ALS Act.

Issues related to Drug Enforcement Agency (DEC) implementation of S. 916; Reimbursement issues; issues related to opioid addiction; issues related to NIH/HHS funding levels; issues related to funding for CARA, medication assisted treatment and 21st Century Cures Act; Implementation of CARA Act. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 4712 Fairness in Orphan Drug Exclusivity Act. Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136. Policies impacting orphan drug approval and reimbursement, including H.R. 4712/S. 3272, Fairness in Orphan Drug Exclusivity Act.

General education about policies impact pharmaceutical development, approval, and reimbursement including Medicare payment policies. Medicare Part D. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019. Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136. Education regarding Executive Orders impacting drug pricing including Medicare rebate reform, the 340 B program, "buy America" proposals, and proposals to impose "most favored nation" pricing on Medicare Part B and D.

General education about federal policies impact pharmaceutical development, approval, and reimbursement (including Medicare, Medicaid, ACA issues). General education about FDA approval policies; Drug pricing under 340B Program; IPI drug pricing proposal. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019. Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136. Education regarding Executive Orders impacting drug pricing including Medicare rebate reform, the 340 B program, "buy America" proposals, and proposals to impose "most favored nation" pricing on Medicare Part B and D.

General education about policies impacting pharmaceutical development, approval and reimbursement; Drug safety and drug counterfeiting; Medicare Part D; Federal preemption for prescription drugs; drug importation; and drug shortages. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019. Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136.

Medicare payment issues including the Independent Payment Advisory Board (IPAB) and Medicaid issues. Medicare Part D. 101 drug pricing. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019. Vaccine legislation; H.R. 5076, S. 1872. Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136.

General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Rebates for Medicare Part D. Importation. 340B Drug Pricing Program. IPI drug pricing proposal, Medicare Rebate Rule. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019. Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136. H.R. 1425, Patient Protection and Affordable Care Enhancement Act

General education about policies impacting pharmaceutical development, approval and reimbursement. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019. FY 2021 Appropriations. Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136.

Policies impacting Medicare Part D and Part B reimbursement policies. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019. Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136.

Legislative issues related to insurance markets; ACA implementation issues; PBM legislation. Policies impacting U.S. address to the COVID-19 pandemic, including H.R. 6201, Families First Coronavirus Response Act and H.R. 748.

Legislative and regulatory issues regarding Medicaid managed care; Medicare Advantage issues. S. 1895. Policies impacting U.S. address to the COVID-19 pandemic, including H.R. 6201, Families First Coronavirus Response Act and H.R. 748.

General education about federal policies impact pharmaceutical development, approval, and reimbursement (including Medicare, Medicaid, ACA issues). General education about FDA approval policies; Drug pricing under 340B Program; IPI drug pricing proposal. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019. Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136.

General education about policies impact pharmaceutical development, approval, and reimbursement including Medicare payment policies. Medicare Part D. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019. Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136.

Issues related to Drug Enforcement Agency (DEC) implementation of S. 916; Reimbursement issues; issues related to opioid addiction; issues related to NIH/HHS funding levels; issues related to funding for CARA, medication assisted treatment and 21st Century Cures Act; Implementation of CARA Act. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 4712 Fairness in Orphan Drug Exclusivity Act. Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136. Policies impacting orphan drug approval and reimbursement, including H.R. 4712/S. 3272, Fairness in Orphan Drug Exclusivity Act.

S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019; Issues concerning BARDA funding; S. 551, Recovering Excessive Funds for Unused and Needless Drugs Act 2019; Drug importation including S. 61 and H.R. 478, Safe and Affordable Drugs from Canada Act of 2019; S. 97 and H.R. 447, Affordable and Safe Prescription Drug Importation Act; Legislation affecting pharmaceutical pricing including the Lower Heath Care Costs Act of 2019 (S.1895), Affordable Prescriptions for Patients Act of 2019 (S. 1416), Fair Accountability and Innovative Research Drug Pricing Act of 2019 (S. 1391, Transparent Drug Pricing Act of 2019 (S. 977), CREATES Act of 2019 (H.R. 965, S. 340), Medicare Negotiation and Competitive Licensing Act of 2019 (H.R. 1046), Strengthening Health Care and Lowering Prescription Drug Costs Act (H.R. 987). Policies impacting the U.S. response to the COVID-19 pandemic including H.R. 604, the Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No. 116-123; H.R. 6201, Families First Coronavirus Response Act, Public Law No. 116-127; H.R. 748, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act"), Public Law No. 116-136; and H.R. 6800, the Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES Act"). H.R. 2279/S.2546, the Safe Step Act. Policies to ensure an adequate supply of plasma generally and for the development of therapies for COVID-19.

Federal funding for alcohol research at NIH; Medical research provisions in Labor, Health and Human Services, and Education Appropriations bill; Legislation concerning alcohol, alcohol-related diseases, and substance abuse; Security of medical research. Policies impacting the U.S. response to the COVID-19 pandemic including H.R. 604, the Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No. 116-123; H.R. 6201, Families First Coronavirus Response Act, Public Law No. 116-127; H.R. 748, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), Public Law No. 116-136; and H.R. 6800, the Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES Act").

Payment policies for Medicare Part B prescription drugs; Medicare drug coverage and payment policies for plasma protein products. Medicare coverage and payment for home infusion of drugs generally and during the COVID-19 public health emergency. Policies impacting the U.S. response to the COVID-19 pandemic including H.R. 604, the Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No. 116-123; H.R. 6201, Families First Coronavirus Response Act, Public Law No. 116-127; H.R. 748, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), Public Law No. 116-136; and H.R. 6800, the Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES Act). S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019.

Drug safety and drug counterfeiting; H.R. 2905, Medicare IVIG Access Enhancement Act; Policies affecting pre-existing condition protections; Drug importation including S. 61 and H.R. 478, Safe and Affordable Drugs from Canada Act of 2019; S. 97 and H.R. 447, Affordable and Safe Prescription Drug Importation Act; S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3; Lower Drug Costs Now Act of 2019; Policies impacting the U.S. response to the COVID-19 pandemic including H.R. 604, the Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No. 116-123; H.R. 6201, Families First Coronavirus Response Act, Public Law No. 116-127; H.R. 748, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act"), Public Law No. 116-136; and H.R. 6800, the Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES Act").

Medicare coverage and reimbursement for therapy services and rehabilitation telehealth services including H.R. 7154, the Outpatient Therapy Modernization and Stabilization Act; Policies impacting the U.S. response to the COVID-19 pandemic including H.R. 604, the Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No. 116-123; H.R. 6201, Families First Coronavirus Response Act, Public Law No. 116-127; H.R. 748, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), Public Law No. 116-136; and H.R. 6800, the Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES Act). Medicare payment reform for post acute care services. Matters affecting bundled payments and value-based reimbursement; Implementation of physician fee schedule for CY 2020.

Coverage of physical therapy assistants under TRICARE; Implementation of National Defense Authorization Act for FY 2018.

Matters affecting access to and pricing of pharmaceuticals. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and HR 3, Lower Drug Costs Now Act of 2019. Policies impacting the U.S. response to the COVID-19 pandemic including H.R. 604, the Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No. 116-123; H.R. 6201, Families First Coronavirus Response Act, Public Law No. 116-127; H.R. 748, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), Public Law No. 116-136; and H.R. 6800, the Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES Act). Medicare coverage and payment for home infusion of drugs during the COVID-19 pandemic public health emergency.

Matters affecting access to and pricing of pharmaceuticals; matters affecting the Orphan Drug Act and therapies for rare diseases; legislation and regulatory activity relating to importation of prescription drugs, including S. 61 and H.R. 478, Safe and Affordable Drugs from Canada Act of 2019; S. 97 and H.R. 447, Affordable and Safe Prescription Drug Importation Act; S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3; Lower Drug Costs Now Act of 2019; Policies impacting the U.S. response to the COVID-19 pandemic including H.R. 604, the Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No. 116-123; H.R. 6201, Families First Coronavirus Response Act, Public Law No. 116-127; H.R. 748, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), Public Law No. 116-136; and H.R. 6800, the Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES Act").

Tax issues affecting the pharmaceutical industry including international tax. Implementation of the Tax Cuts and Jobs Act (P.L. 115-97).

General education about policies impacting pharmaceutical development, approval and reimbursement; Drug safety and drug counterfeiting; Medicare Part D; Federal preemption for prescription drugs; drug importation; and drug shortages. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019. Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136.

General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Rebates for Medicare Part D. Importation. 340B Drug Pricing Program. IPI drug pricing proposal, Medicare Rebate Rule. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019. Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136.

General education about policies impacting pharmaceutical development, approval and reimbursement. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019. FY 2021 Appropriations. Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136.

Policies impacting Medicare Part D and Part B reimbursement policies. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019. Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136.

Legislative and regulatory issues regarding Medicaid managed care; Medicare Advantage issues. S. 1895. Policies impacting U.S. address to the COVID-19 pandemic, including H.R. 6201, Families First Coronavirus Response Act and H.R. 748.

Legislative issues related to insurance markets; ACA implementation issues; PBM legislation. Policies impacting U.S. address to the COVID-19 pandemic, including H.R. 6201, Families First Coronavirus Response Act and H.R. 748.

Federal funding for alcoholism research at NIH; Medical research provisions in Labor, Health and Human Services, and Education Appropriations bill; Legislation concerning alcoholism, alcohol-related diseases, and substance abuse; Security of medical research.

Drug safety and drug counterfeiting; H.R. 2905, Medicare IVIG Access Enhancement Act; Policies affecting pre-existing condition protections; Drug importation including S. 61 and H.R. 478, Safe and Affordable Drugs from Canada Act of 2019; S. 97 and H.R. 447, Affordable and Safe Prescription Drug Importation Act; S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019; Supply of intravenous immunoglobulin. S.3548/H.R. 748, Coronavirus Aid, Relief, and Economic Security Act; H.R. 6201, Families First Coronavirus Response Act; and H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020.

Tax legislation affecting the Orphan Drug Tax Credit and the Research and Development Tax Credit.

Medicare coverage and reimbursement for therapy services; Medicare payment reform for post acute care services Matters affecting bundled payments and value-based reimbursement; Implementation of physician fee schedule for CY 2020.

Physical Therapist Workforce and Patient Access Act (S. 970). S.3548/H.R. 748, Coronavirus Aid, Relief, and Economic Security Act; H.R. 6201, Families First Coronavirus Response Act; and H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020.

Coverage of physical therapy assistants under TRICARE; Implementation of National Defense Authorization Act for FY 2018.

Matters affecting access to and pricing of pharmaceuticals; matters affecting the Orphan Drug Act and therapies for rare diseases; legislation and regulatory activity relating to importation of prescription drugs, including S. 61 and H.R. 478, Safe and Affordable Drugs from Canada Act of 2019; S. 97 and H.R. 447, Affordable and Safe Prescription Drug Importation Act; Implementation of the Right to Try Act of 2017. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019; S.3548/H.R. 748, Coronavirus Aid, Relief, and Economic Security Act; H.R. 6201, Families First Coronavirus Response Act; and H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020.

Matters affecting access to and pricing of pharmaceuticals. S 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and HR 3, Lower Drug Costs Now Act of 2019.

Tax issues affecting the pharmaceutical industry and the Orphan Drug tax Credit.

S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019; Issues concerning BARDA funding; S. 551, Recovering Excessive Funds for Unused and Needless Drugs Act 2019; Drug importation including S. 61 and H.R. 478, Safe and Affordable Drugs from Canada Act of 2019; S. 97 and H.R. 447, Affordable and Safe Prescription Drug Importation Act; Legislation affecting pharmaceutical pricing including the Lower Heath Care Costs Act of 2019 (S.1895), Affordable Prescriptions for Patients Act of 2019 (S. 1416), Fair Accountability and Innovative Research Drug Pricing Act of 2019 (S. 1391, Transparent Drug Pricing Act of 2019 (S. 977), CREATES Act of 2019 (H.R. 965, S. 340), Medicare Negotiation and Competitive Licensing Act of 2019 (H.R. 1046), Strengthening Health Care and Lowering Prescription Drug Costs Act (H.R. 987). S.3548/H.R. 748, Coronavirus Aid, Relief, and Economic Security Act; H.R. 6201, Families First Coronavirus Response Act; and H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020. H.R. 2279/S.2546, the Safe Step Act.

Issues related to Drug Enforcement Agency (DEC) implementation of S. 916; Reimbursement issues; issues related to opioid addiction; issues related to NIH/HHS funding levels; issues related to funding for CARA, medication assisted treatment and 21st Century Cures Act; Implementation of CARA Act. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 4712 Fairness in Orphan Drug Exclusivity Act. Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136.

General education about policies impact pharmaceutical development, approval, and reimbursement including Medicare payment policies. Medicare Part D. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019. Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136.

General education about federal policies impact pharmaceutical development, approval, and reimbursement (including Medicare, Medicaid, ACA issues). General education about FDA approval policies; Drug pricing under 340B Program; IPI drug pricing proposal. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019. Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136.

Medicare payment issues including the Independent Payment Advisory Board (IPAB) and Medicaid issues. Medicare Part D. 101 drug pricing. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 1865, Further Consolidation Appropriations Act 2020.

Tax issues affecting the pharmaceutical industry including international tax. Implementation of the Tax Cuts and Jobs Act (P.L. 115-97).

General education about policies impacting pharmaceutical development, approval and reimbursement; Drug safety and drug counterfeiting; Medicare Part D; Federal preemption for prescription drugs; drug importation; and drug shortages. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 1865, Further Consolidation Appropriations Act 2020.

General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Rebates for Medicare Part D. Importation. 340B Drug Pricing Program. IPI drug pricing proposal, Medicare Rebate Rule. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 1865, Further Consolidated Appropriations Act 2020.

Policies impacting Medicare Part D and Part B reimbursement policies. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 1865, Further Consolidated Appropriations Act 2020.

General education about policies impacting pharmaceutical development, approval and reimbursement. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 1865, Further Consolidated Appropriations Act 2020.

Legislative issues related to insurance markets; ACA implementation issues; PBM legislation.

Legislative and regulatory issues regarding Medicaid managed care; Medicare Advantage issues. S. 1895.

Federal funding for alcoholism research at NIH; Medical research provisions in Labor, Health and Human Services, and Education Appropriations bill; H.R. 1865, Further Consolidated Appropriations Act 2020; Legislation concerning alcoholism, alcohol-related diseases, and substance abuse; Security of medical research.

S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019; Issues concerning BARDA funding; S. 551, Recovering Excessive Funds for Unused and Needless Drugs Act 2019; Drug importation including S. 61 and H.R. 478, Safe and Affordable Drugs from Canada Act of 2019; S. 97 and H.R. 447, Affordable and Safe Prescription Drug Importation Act; Legislation affecting pharmaceutical pricing including the Lower Heath Care Costs Act of 2019 (S.1895), Affordable Prescriptions for Patients Act of 2019 (S. 1416), Fair Accountability and Innovative Research Drug Pricing Act of 2019 (S. 1391, Transparent Drug Pricing Act of 2019 (S. 977), CREATES Act of 2019 (H.R. 965, S. 340), Medicare Negotiation and Competitive Licensing Act of 2019 (H.R. 1046), Strengthening Health Care and Lowering Prescription Drug Costs Act (H.R. 987).

S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019; Medicare prescription drug benefit;government negotiation/rebates for Medicare Part D; discounts in the Medicare Part D donut hole and drug company payments in the catastrophic benefit; coverage and payment policies for Medicare Part B prescription drugs; international reference pricing proposals (S. 977); and the "most favored nation" pricing; H.R. 1865, Further Consolidated Appropriations Act 2020.